Protalix BioTherapeutics Inc. (PLX) Company Profile & Statistics

Protalix BioTherapeutics Inc.
PLX
(AMEX)
N/A
1.17
-0.04 (-3.31%)
in:usd•As of: May 02, 2024 15:02 UTC -4
Open
1.18
High
1.19
Low
1.17

About Protalix BioTherapeutics Inc.

CEO

Dror Bashan

Headquarters

2 university plaza, suite 100

hackensack, nj 07601, united states

Auditor

Kesselman & Kesselman

Employees

208

Share Holders

Website

www.protalix.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.

Protalix BioTherapeutics Inc. Statistics

Valuation Measures

Market Capitalization ²	85.78M
Enterprise Value	82.40M
Enterprise Value/EBITDA (ttm)	6.91
Price to Earnings Ratio (ttm)	22.80
Price to Book (mrq)	2.43
Price to Sales (ttm)	1.28
Price to Cash (ytd)	8.35

Profitability

Gross Margin (ttm)	54.64%
Operating Margin (ttm)	12.69%
Profit Margin (ttm)	-13.27%
Return on Equity (ttm)	29.73%
Return on Invested Capital (ttm)	-0.84%
Return on Assets (ttm)	10.17%

Income Statement

Revenue (ttm)	65.49M
Revenue Per Share (ttm)	0.90
Gross Profit (ttm)	42.51M
EBITDA (ttm)³	11.92M
Net Income Avi to Common (ttm)	8.31M
Diluted EPS (ttm)	0.05

Share Statistics

Beta (5Y Monthly)	0.90
52-Week Change	-55.68%
S&P500 52-Week Change	24.92%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	73.05M
Dividend Yield	0.00%
Float ⁴	69.42M
% Held by Insiders	4.97%
% Held by Institutions	16.53%

Balance Sheet

Total Cash (mrq)	44.56M
Total Cash Per Share (mrq)	0.61
Total Debt (mrq)	20.25M
Total Debt/Equity (mrq)	60.33%
Current Ratio (mrq)	1.54%
Quick Ratio (mrq)	1.12%
Book Value Per Share (mrq)	0.46

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.02
Free Cash Flow (ytd)	-2.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Protalix BioTherapeutics Inc.

Trade With A Regulated Broker